Trevigen-DNA Damage細胞損傷分析系列


                                                 


PARP in vivo Pharmacodynamic Assay II



PARP catalyzes the NAD-dependent addition of poly (ADP-ribose) (PAR) onto itself and adjacent nuclear proteins. Furthermore, polymorphisms in the PARP-1 gene correspond to disease predisposition, and variation in PARP activity might have an impact on the effects of PARP inhibitors in clinical settings. To address the need to monitor PARP activity among different individuals, and within cells, Trevigen's improved validated PARP in vivo Pharmacodynamic Assay II measures net PAR levels in cellular extracts and has been used to document differences in PAR levels among tumor lysates from different tissues, organs and xenografts. The HT PARP in vivo Pharmacodynamic Assay II employs a purified, pre-coated monoclonal PAR antibody as the capture agent, and anti-PAR polyclonal rabbit antibody as the detecting agent.








































































































PARP產品特點



·  Fewer user steps


·  Pre-coated 96 well capture antibody plates


·  High signal to noise ratio


·  Detection sensitivity of 2 pg/ml of PAR


·  Broad linear dynamic range to 1,000 pg/ml


·  Reduced inter-assay variability


·  Commercially available validated assay that measures drug action on PARP in both in vivo and in vitro settings



 



PARP產品應用:



·  Quantification of PAR in peripheral blood mononuclear cells, tissue culture cells, and tumor lysates from different tissues, organs and xenografts.


·  Monitoring the efficacy of PARP inhibitors on PAR formation in vivo.


·  Verifying observations of enhanced cancer cell cytotoxicity arising from PARP inhibitor/anticancer drug combination therapy.


·  Facilitating development of PARP and PARG targeted therapeutics



 



Components:



Part #



Component



Size



 



4520-096-01



PAR Standard, 25 pg/μl



5 x 20 μl



 



4520-096-02



Sample Buffer



20 ml



 



4520-096-03



PAR Polyclonal Detecting Antibody



30 μl



 



4520-096-04



Goat anti-Rabbit IgG-HRP



30 μl



 



4675-096-01



PARP PeroxyGlow A



6 ml



 



4675-096-02



PARP PeroxyGlow B



6 ml



 



4520-096-05



Cell Lysis Reagent



30 ml



 



4520-096-06



DNase 1, 2 Units/μl



60 μl



 



4520-096-07



100X Magnesium Cation



500 μl



 



4520-096-P



Pre-coated white 96-stripwell plate, and 5 sealers



1 plate



 



4520-096-08



Jurkat Cell Lysate Standard Control, Low



600 μl



 



4520-096-09



Jurkat Cell Lysate Standard Control, Medium



600 μl



 



4520-096-10



Jurkat Cell Lysate Standard Control, High



600 μl



 



4520-096-11



Antibody Diluent



15 ml



 



4520-096-12



20% (w/v) SDS



1 ml



 



Storage:



Components are stored at -80°C , -20°C , 4°C , and room temperature



 



References:



1. Virag, L., and Szabo, C. 2002. The therapeutic potential of Poly(ADP-Ribose) Polymerase inhibitors. Pharmacological Reviews 54:375-429.

2. Thiemermann, C., J. Bowes, F.P. Myint, and J.R. Vane. 1997. Inhibition of the activity of poly(ADP-ribose) synthase reduces ischemia-reperfusion injury in the heart and skeletal muscle. Proc Natl Acad Sci USA 94:679-83.

3. Curtin NJ. 2005. PARP inhibitors for cancer therapy. Expert Rev Mol Med 7:1-20.

4. Kinders JK, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE, and the National Cancer Institute Phase 0 Clinical Trials Team. 2008. Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) polymerase in Tumor Biopsies of Mouse Xenografts. Clin Cancer Res 14:6877-85.




詳細產品資訊,請登錄www.trevigen.com 查詢,或與太鼎生物科技有限公司(02)86609496聯繫。 


更多參考內容:


WWW.BIOPIONEER.COM.TW


 太鼎生物科技有限公司(02)86609496

arrow
arrow
    全站熱搜

    太鼎生物科技 發表在 痞客邦 留言(0) 人氣()